$848.50 - $6,050.50

$848.50 - $6.00

Choose an Option...
  • 100 mg - $6,050.50
  • 50 mg - $4,277.50
  • 25 mg - $2,842.00
  • 5 mg - $848.50
  • Custom Amount (Quotes Only)
In stock
Only %1 left
You may also be interested in:

Product Description

The 53-6.7 monoclonal antibody reacts with mouse CD8α. The CD8 antigen is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor (TCR). Like the TCR, CD8 binds to class I MHC molecules displayed by antigen presenting cells (APC). CD8 is primarily expressed on the surface of cytotoxic T cells, but can also be found on thymocytes, natural killer cells, and some dendritic cell subsets. CD8 most commonly exists as a heterodimer composed of one CD8α and one CD8β chain however, it can also exist as a homodimer composed of two CD8α chains. Both the CD8α and CD8β chains share significant homology to immunoglobulin variable light chains. The molecular weight of each CD8 chain is approximately 34 kDa. The 53-6.7 antibody exhibits depleting activity when used in vivo.

Specifications

Isotype Rat IgG2a, κ
Recommended Isotype Control(s) InVivoPlus rat IgG2a isotype control, anti-trinitrophenol
Recommended Dilution Buffer InVivoPure pH 6.5 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Immunogen Mouse Spleen Cells or Thymocyte Membranes
Reported Applications in vivo CD8+ T cell depletion
Immunofluorescence
Flow cytometry
Western blot
Formulation PBS, pH 6.5
Contains no stabilizers or preservatives
Endotoxin* ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL assay
Aggregation* <5%
Determined by SEC
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein G
RRID AB_1107671
Molecular Weight 150 kDa
Murine Pathogen Tests* Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options
* Additional quality control measures for our InVivoPlusâ„¢ products include advanced binding validation, murine pathogen screening, protein aggregation screening, and ultra-low endotoxin levels. The superior quality of our InVivoPlusâ„¢ products will meet and exceed the strict demands and rigorous standards required for in vivo research. Learn more about the InVivoPlusâ„¢ difference here.

Application References

  • in vivo CD8+ T cell depletion Flow Cytometry
    Uddin, M. N., et al (2014). "TNF-alpha-dependent hematopoiesis following Bcl11b deletion in T cells restricts metastatic melanoma" J Immunol 192(4): 1946-1953.

    Using several tumor models, we demonstrate that mice deficient in Bcl11b in T cells, although having reduced numbers of T cells in the peripheral lymphoid organs, developed significantly less tumors compared with wild-type mice. Bcl11b(-/-) CD4(+) T cells, with elevated TNF-alpha levels, but not the Bcl11b(-/-) CD8(+) T cells, were required for the reduced tumor burden, as were NK1.1(+) cells, found in increased numbers in Bcl11b(F/F)/CD4-Cre mice. Among NK1.1(+) cells, the NK cell population was predominant in number and was the only population displaying elevated granzyme B levels and increased degranulation, although not increased proliferation. Although the number of myeloid-derived suppressor cells was increased in the lungs with metastatic tumors of Bcl11b(F/F)/CD4-Cre mice, their arginase-1 levels were severely reduced. The increase in NK cell and myeloid-derived suppressor cell numbers was associated with increased bone marrow and splenic hematopoiesis. Finally, the reduced tumor burden, increased numbers of NK cells in the lung, and increased hematopoiesis in Bcl11b(F/F)/CD4-Cre mice were all dependent on TNF-alpha. Moreover, TNF-alpha treatment of wild-type mice also reduced the tumor burden and increased hematopoiesis and the numbers and activity of NK cells in the lung. In vitro treatment with TNF-alpha of lineage-negative hematopoietic progenitors increased NK and myeloid differentiation, further supporting a role of TNF-alpha in promoting hematopoiesis. These studies reveal a novel role for TNF-alpha in the antitumor immune response, specifically in stimulating hematopoiesis and increasing the numbers and activity of NK cells.

  • in vivo CD8+ T cell depletion Flow Cytometry
    Wang, W., et al (2018). "RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer" Cancer Cell 34(5): 757-774 e757.

    Pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance and immunotherapeutic resistance. We discovered upregulation of receptor-interacting serine/threonine protein kinase 1 (RIP1) in tumor-associated macrophages (TAMs) in PDA. To study its role in oncogenic progression, we developed a selective small-molecule RIP1 inhibitor with high in vivo exposure. Targeting RIP1 reprogrammed TAMs toward an MHCII(hi)TNFalpha(+)IFNgamma(+) immunogenic phenotype in a STAT1-dependent manner. RIP1 inhibition in TAMs resulted in cytotoxic T cell activation and T helper cell differentiation toward a mixed Th1/Th17 phenotype, leading to tumor immunity in mice and in organotypic models of human PDA. Targeting RIP1 synergized with PD1-and inducible co-stimulator-based immunotherapies. Tumor-promoting effects of RIP1 were independent of its co-association with RIP3. Collectively, our work describes RIP1 as a checkpoint kinase governing tumor immunity.

  • in vivo CD8+ T cell depletion Flow Cytometry
    Hafalla, J. C., et al (2012). "The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology" PLoS Pathog 8(2): e1002504.

    The balance between pro-inflammatory and regulatory immune responses in determining optimal T cell activation is vital for the successful resolution of microbial infections. This balance is maintained in part by the negative regulators of T cell activation, CTLA-4 and PD-1/PD-L, which dampen effector responses during chronic infections. However, their role in acute infections, such as malaria, remains less clear. In this study, we determined the contribution of CTLA-4 and PD-1/PD-L to the regulation of T cell responses during Plasmodium berghei ANKA (PbA)-induced experimental cerebral malaria (ECM) in susceptible (C57BL/6) and resistant (BALB/c) mice. We found that the expression of CTLA-4 and PD-1 on T cells correlates with the extent of pro-inflammatory responses induced during PbA infection, being higher in C57BL/6 than in BALB/c mice. Thus, ECM develops despite high levels of expression of these inhibitory receptors. However, antibody-mediated blockade of either the CTLA-4 or PD-1/PD-L1, but not the PD-1/PD-L2, pathways during PbA-infection in ECM-resistant BALB/c mice resulted in higher levels of T cell activation, enhanced IFN-gamma production, increased intravascular arrest of both parasitised erythrocytes and CD8(+) T cells to the brain, and augmented incidence of ECM. Thus, in ECM-resistant BALB/c mice, CTLA-4 and PD-1/PD-L1 represent essential, independent and non-redundant pathways for maintaining T cell homeostasis during a virulent malaria infection. Moreover, neutralisation of IFN-gamma or depletion of CD8(+) T cells during PbA infection was shown to reverse the pathologic effects of regulatory pathway blockade, highlighting that the aetiology of ECM in the BALB/c mice is similar to that in C57BL/6 mice. In summary, our results underscore the differential and complex regulation that governs immune responses to malaria parasites.

  • in vivo CD8+ T cell depletion
    Christensen, A. D., et al (2015). "Depletion of regulatory T cells in a hapten-induced inflammation model results in prolonged and increased inflammation driven by T cells" Clin Exp Immunol 179(3): 485-499.

    Regulatory T cells (Tregs ) are known to play an immunosuppressive role in the response of contact hypersensitivity (CHS), but neither the dynamics of Tregs during the CHS response nor the exaggerated inflammatory response after depletion of Tregs has been characterized in detail. In this study we show that the number of Tregs in the challenged tissue peak at the same time as the ear-swelling reaches its maximum on day 1 after challenge, whereas the number of Tregs in the draining lymph nodes peaks at day 2. As expected, depletion of Tregs by injection of a monoclonal antibody to CD25 prior to sensitization led to a prolonged and sustained inflammatory response which was dependent upon CD8 T cells, and co-stimulatory blockade with cytotoxic T lymphocyte antigen-4-immunoglobulin (CTLA-4-Ig) suppressed the exaggerated inflammation. In contrast, blockade of the interleukin (IL)-10-receptor (IL-10R) did not further increase the exaggerated inflammatory response in the Treg -depleted mice. In the absence of Tregs , the response changed from a mainly acute reaction with heavy infiltration of neutrophils to a sustained response with more chronic characteristics (fewer neutrophils and dominated by macrophages). Furthermore, depletion of Tregs enhanced the release of cytokines and chemokines locally in the inflamed ear and augmented serum levels of the systemic inflammatory mediators serum amyloid (SAP) and haptoglobin early in the response.

Product Citations

  • Neutrophil depletion at the early stage of Japanese encephalitis virus infection affects CD8+ T cell infiltration into the mouse brain and causes severe encephalitis.

    In Front Immunol on 6 February 2026 by Soni, R., Jena, P., et al.

    PubMed

    Neutrophils have been reported to have protective and detrimental functions in viral infections. However, the role of neutrophils remains unexplored in Japanese encephalitis virus (JEV) infection. In this study, we elucidated the dynamics of neutrophils and their influence on immune cell recruitment in subclinical and severe encephalitis in mouse models. Further, we depleted neutrophils from 3-4 week-old C57BL/6 mice using mAb1A8 (anti-Ly6G) antibody and studied their association with inflammation, viral replication, immune cell infiltration and disease outcome. We observed that an increase in JEV replication is associated with increased infiltration of neutrophils in the spleen and brain. Further studies confirmed that depletion of neutrophils at an early stage of JEV infection reduced CD8 abundance in the infected brain and accelerated death in mice. We also observed that inhibition of the CXCL12-CXCR4 signalling axis by antagonist AMD3100 reduced CD8 abundance in the brain and augmented inflammasome activation, leading to fatal encephalitis. Reduced CXCR4 levels in the spleen and blood of CD8+T cells correlated with enhanced Granzyme B level, indicating CD8 cells differentiated more into effector phenotypes in neutrophil-depleted mice. Furthermore, CD8 depletion delayed the death of mice infected with a sublethal strain compared to neutrophil-depleted mice, suggesting that neutrophils play a vital role in the early restriction of viral replication, whereas CD8 is essential later in clearing the virus. Taken together, our study sheds new light on the role of neutrophils in the pathogenic mechanisms of JEV encephalitis and highlights the importance of neutrophils and CD8 cells associated with disease outcomes.

  • Neutrophil depletion at the early stage of Japanese encephalitis virus infection affects CD8+ T cell infiltration into the mouse brain and causes severe encephalitis.

    In Front Immunol on 6 February 2026 by Soni, R., Jena, P., et al.

    PubMed

    Neutrophils have been reported to have protective and detrimental functions in viral infections. However, the role of neutrophils remains unexplored in Japanese encephalitis virus (JEV) infection. In this study, we elucidated the dynamics of neutrophils and their influence on immune cell recruitment in subclinical and severe encephalitis in mouse models. Further, we depleted neutrophils from 3-4 week-old C57BL/6 mice using mAb1A8 (anti-Ly6G) antibody and studied their association with inflammation, viral replication, immune cell infiltration and disease outcome. We observed that an increase in JEV replication is associated with increased infiltration of neutrophils in the spleen and brain. Further studies confirmed that depletion of neutrophils at an early stage of JEV infection reduced CD8 abundance in the infected brain and accelerated death in mice. We also observed that inhibition of the CXCL12-CXCR4 signalling axis by antagonist AMD3100 reduced CD8 abundance in the brain and augmented inflammasome activation, leading to fatal encephalitis. Reduced CXCR4 levels in the spleen and blood of CD8+T cells correlated with enhanced Granzyme B level, indicating CD8 cells differentiated more into effector phenotypes in neutrophil-depleted mice. Furthermore, CD8 depletion delayed the death of mice infected with a sublethal strain compared to neutrophil-depleted mice, suggesting that neutrophils play a vital role in the early restriction of viral replication, whereas CD8 is essential later in clearing the virus. Taken together, our study sheds new light on the role of neutrophils in the pathogenic mechanisms of JEV encephalitis and highlights the importance of neutrophils and CD8 cells associated with disease outcomes.

  • Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas.

    In Cancer Cell on 8 December 2025 by Cheung, J. F., Hunt, B. G., et al.

    PubMed

    T cells edit tumors by eliminating neoantigen-expressing tumor cells. Yet, how and when this is achieved remains uncertain. Using a murine sarcoma model with fluorescent neoantigens, we found that tumors developed later and in fewer T cell-sufficient mice (∼53% penetrance) than T cell-deficient mice (∼100%). With T cells, all emergent tumor cells had silenced neoantigens, but neoantigen-negative tumor cells were also present in every T cell-deficient mouse. This suggested silencing was necessary but not sufficient for outgrowth. Genetic removal of neoantigens restored tumor penetrance if implemented on day 5 post-tumor initiation, but not day 10, because CD8+ and CD4+ T cells infiltrated the tissue and eliminated most neoantigen-positive and -negative tumor cells within 8 days. Single-cell analyses on day-7 tumors showed oncogenic changes including increased proliferation and T cell-dependent upregulation of the IFNγ-response gene Cd274 (PD-L1). T cell-depletion rescued both neoantigen-positive and -negative cells, while IFNγ blockade rescued only negative cells. This shows that T cells efficiently edit sarcomas of neoantigens and prevent early tumors via IFNγ-independent and IFNγ-dependent (bystander) mechanisms.

  • A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors.

    In Exploration (Beijing) on 1 December 2025 by Wang, Y. J., Jiang, W. J., et al.

    PubMed

    Rapid advances in synthetic biology are driving the development of microbes as therapeutic agents. While the immunosuppressive tumor microenvironment creates a favorable niche for the systematic delivery of bacteria and therapeutic payloads, these can be harmful if released into healthy tissues. To address this limitation, we designed a spatiotemporal targeting system for engineered Escherichia coli Nissle 1917, controlled by azide-modified hyaluronic acid hydrogel and near-infrared radiation induction. Using a temperature-driven genetic status switch, the system produced durable therapeutic output and promoted the therapeutic activity in solid tumors. The combination of azide-modified hyaluronic acid hydrogel and temperature-sensitive, engineered Escherichia coli Nissle 1917 provided spatiotemporal targeting of solid tumors, not only showing significant therapeutic effects on primary solid tumors, but also inhibiting the metastasis and recurrence of cancer cells by enhancing tumor-infiltrating lymphocytes. This system has potential for clinical application.

Product FAQs

Related Products

  1. Catalog #BP0117
    InVivoPlus anti-mouse CD8α Read more
  2. Catalog #BP0061
    InVivoPlus anti-mouse CD8α Read more
  3. Catalog #BE0061
    InVivoMAb anti-mouse CD8α Read more
  4. Catalog #BE0117
    InVivoMAb anti-mouse CD8α Read more
  5. Catalog #BE0004-2
    InVivoMAb anti-human CD8α Read more
  6. Catalog #CP134
    RecombiMAb anti-mouse CD8α Read more
  7. Catalog #BE0415
    InVivoMAb anti-rat CD8α Read more

Additional Formats

  1. Catalog #BE0004-1
    InVivoMAb anti-mouse CD8α Read more